| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Merck & Co. Inc. (SN: MRK)
MRK Technical Analysis
3
| As on 4th Jan 2023 MRK SHARE Price closed @ 109.80 and we RECOMMEND Buy for LONG-TERM with Stoploss of 33.68 & Buy for SHORT-TERM with Stoploss of 85.64 we also expect STOCK to react on Following IMPORTANT LEVELS. |
MRKSHARE Price
| Open | 111.50 | Change | Price | % |
| High | 111.50 | 1 Day | 0.00 | 0.00 |
| Low | 109.80 | 1 Week | 23.92 | 27.85 |
| Close | 109.80 | 1 Month | 28.95 | 35.81 |
| Volume | 30 | 1 Year | 28.08 | 34.36 |
| 52 Week High 187.55 | 52 Week Low 71.18 | ||||
SN Chile Most Active Stocks
| ITAUCORP | 1.79 | -2.19% |
| LTM | 7.00 | 0.43% |
| HF | 1311.50 | -0.58% |
| ENELCHILE | 49.25 | 0.51% |
| BSANTANDER | 37.28 | -0.24% |
| ENJOY | 1.00 | 0.00% |
| VAPORES | 55.88 | -1.71% |
| ENELAM | 111.80 | 1.63% |
| IANSA | 14.30 | 0.00% |
| CHILE | 84.45 | 0.56% |
SN Chile Top Gainers Stocks
SN Chile Top Losers Stocks
| AXP | 173.97 | -97.40% |
| AXP | 173.97 | -97.40% |
| AXP | 173.97 | -97.40% |
| AXP | 173.97 | -97.40% |
| CEM | 100.00 | -66.67% |
| CEM | 100.00 | -66.67% |
| CEM | 100.00 | -66.67% |
| SCOTIABKCL | 279.99 | -9.67% |
| MULTIFOODS | 270.00 | -4.85% |
| HABITAT | 733.34 | -2.74% |
| MRK Daily Charts |
MRK Intraday Charts |
Whats New @ Bazaartrend |
MRK Free Analysis |
|
|
MRK Important Levels Intraday
| RESISTANCE | 113.08 |
| RESISTANCE | 112.03 |
| RESISTANCE | 111.38 |
| RESISTANCE | 110.73 |
| SUPPORT | 108.87 |
| SUPPORT | 108.22 |
| SUPPORT | 107.57 |
| SUPPORT | 106.52 |
MRK Forecast May 2024
| 4th UP Forecast | 335.36 |
| 3rd UP Forecast | 263.02 |
| 2nd UP Forecast | 218.31 |
| 1st UP Forecast | 173.59 |
| 1st DOWN Forecast | 46.01 |
| 2nd DOWN Forecast | 1.29 |
| 3rd DOWN Forecast | -43.42 |
| 4th DOWN Forecast | -115.76 |
MRK Weekly Forecast
| 4th UP Forecast | 117.97 |
| 3rd UP Forecast | 115.35 |
| 2nd UP Forecast | 113.73 |
| 1st UP Forecast | 112.11 |
| 1st DOWN Forecast | 107.49 |
| 2nd DOWN Forecast | 105.87 |
| 3rd DOWN Forecast | 104.25 |
| 4th DOWN Forecast | 101.63 |
MRK Forecast2024
| 4th UP Forecast | 336.74 |
| 3rd UP Forecast | 263.96 |
| 2nd UP Forecast | 218.97 |
| 1st UP Forecast | 173.98 |
| 1st DOWN Forecast | 45.62 |
| 2nd DOWN Forecast | 0.63 |
| 3rd DOWN Forecast | -44.36 |
| 4th DOWN Forecast | -117.14 |
Merck & Co. Inc. ( SN Chile Symbol : MRK )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
MRK Business Profile
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products. The Animal Health segment provides discovers, develops, manufactures, and markets a range of veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as a suite of digitally connected identification, traceability, and monitoring products. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; and Ridgeback Biotherapeutics. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaboration agreement with Gilead Sciences, Inc. to co-develop and co-commercialize long-acting investigational treatment combinations of Lenacapavir and Islatravir in HIV; Amathus Therapeutics to develop treatments for neurodegenerative diseases; and Linnaeus Therapeutics, Inc. to evaluate LNS8801. It also has a collaboration with Biomed X Gmbh for building on ongoing research projects in the fields of oncology and autoimmunity (intestinal epithelial barrier in autoimmune diseases); NGM Biopharmaceuticals, Inc. to focus primarily on the development of medicines in retinal and CVM diseases; and to develop and commercialize tests that identify genetic mutations, as well as with IO Biotech ApS to evaluate IO102-IO103. It also has a partnership with Biocorp Production for the development and supply of a specific version of Mallya device. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey. Address:
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service